S122: ROCK INHIBITORS TARGET SRSF2 LEUKEMIA BY DISRUPTING CELL MITOSIS AND NUCLEAR MORPHOLOGY

• M. Su,
• T. Fleisher,
• I. Grosheva,
• M. Horev,
• M. Olszewska,
• B. Haim,
• A. Plotnikov,
• S. Carvalho,
• Y. Moskovitz,
• M Minden,
• N. Chapal-Ilani,
• E. Papapetrou,
• N. Dezorella,
• T. Cheng,
• N. Kaushansky,
• B Geiger,
• L. Shlush

Affiliations

M. Su

1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

T. Fleisher

3 Molecular and Cellular Biology, Weizmann Institute of Science

I. Grosheva

4 Immunology, Weizmann Institute of Science, Rehovot, Israel

M. Horev

4 Immunology, Weizmann Institute of Science, Rehovot, Israel

M. Olszewska

5 Icahn School of Medicine at Mount Sinai, New York, United States of America

B. Haim

6 Wohl Institute for Drug Discovery, Weizmann Institute of Science, Rehovot, Israel

A. Plotnikov

6 Wohl Institute for Drug Discovery, Weizmann Institute of Science, Rehovot, Israel

S. Carvalho

6 Wohl Institute for Drug Discovery, Weizmann Institute of Science, Rehovot, Israel

Y. Moskovitz

3 Molecular and Cellular Biology, Weizmann Institute of Science

M Minden

7 University Health Network (UHN), Toronto, Canada

N. Chapal-Ilani

3 Molecular and Cellular Biology, Weizmann Institute of Science

E. Papapetrou

8 Icahn School of Medicine at Mount Sinai, New York, United States of America

N. Dezorella

9 Electron Microscopy Unit, Weizmann Institute of Science, Rehovot, Israel

T. Cheng

10 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, Tianjin, China

N. Kaushansky

3 Molecular and Cellular Biology, Weizmann Institute of Science

B Geiger

4 Immunology, Weizmann Institute of Science, Rehovot, Israel

L. Shlush

11 Molecular and Cellular Biology, Weizmann Institute of Science, Rehovot